
Hana Raslova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1843102/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434, 1144-1148.	27.8	3,221
2	Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene, 2004, 23, 4362-4370.	5.9	280
3	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016, 127, 1325-1335.	1.4	261
4	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016, 127, 1317-1324.	1.4	220
5	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. Journal of Clinical Investigation, 2014, 124, 580-591.	8.2	163
6	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 2016, 127, 333-342.	1.4	149
7	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. Journal of Clinical Investigation, 2004, 114, 77-84.	8.2	145
8	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nature Communications, 2012, 3, 717.	12.8	122
9	Human CalDAG-GEFI gene (<i>RASGRP2</i>) mutation affects platelet function and causes severe bleeding. Journal of Experimental Medicine, 2014, 211, 1349-1362.	8.5	117
10	Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood, 2007, 109, 3225-3234.	1.4	108
11	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 2015, 47, 1131-1140.	21.4	107
12	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood, 2012, 120, 2708-2718.	1.4	93
13	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood, 2015, 125, 930-940.	1.4	87
14	Regulation of megakaryocyte maturation and platelet formation. Journal of Thrombosis and Haemostasis, 2009, 7, 227-234.	3.8	86
15	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia, 2016, 30, 999-1002.	7.2	86
16	Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood, 2006, 107, 2303-2310.	1.4	84
17	MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood, 2009, 114, 4221-4232.	1.4	77
18	Megakaryocyte polyploidization is associated with a functional gene amplification. Blood, 2003, 101, 541-544.	1.4	75

#	Article	IF	CITATIONS
19	Megakaryocyte and polyploidization. Experimental Hematology, 2018, 57, 1-13.	0.4	73
20	Germline variants in <i>ETV6</i> underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 ⁺ progenitors. Haematologica, 2017, 102, 282-294.	3.5	70
21	A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. Blood, 2014, 124, 2554-2563.	1.4	69
22	Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro. Cell Death and Disease, 2012, 3, e356-e356.	6.3	68
23	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood, 2012, 120, 2719-2722.	1.4	68
24	Developmental changes in human megakaryopoiesis. Journal of Thrombosis and Haemostasis, 2013, 11, 1730-1741.	3.8	68
25	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
26	Filamin A: key actor in platelet biology. Blood, 2019, 134, 1279-1288.	1.4	62
27	ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell, 2017, 31, 452-465.	16.8	60
28	Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets. Journal of Thrombosis and Haemostasis, 2014, 12, 761-772.	3.8	55
29	Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood, 2011, 118, 6310-6320.	1.4	53
30	P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood, 2008, 111, 4081-4091.	1.4	47
31	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. Oncotarget, 2016, 7, 31980-31992.	1.8	38
32	Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. Nature Communications, 2017, 8, 1786.	12.8	35
33	The abnormal proplatelet formation in MYH9â€related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. Journal of Thrombosis and Haemostasis, 2013, 11, 2163-2175.	3.8	33
34	Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS ONE, 2013, 8, e74257.	2.5	32
35	Progress in understanding the diagnosis and molecular genetics of macrothrombocytopenias. British Journal of Haematology, 2015, 170, 626-639.	2.5	32
36	Susceptibility of mouse mammary glands to murine gammaherpesvirus 72 (MHV-72) infection: evidence of MHV-72 transmission via breast milk. Microbial Pathogenesis, 2001, 31, 47-58.	2.9	30

#	Article	IF	CITATIONS
37	The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia, 2010, 24, 1227-1230.	7.2	30
38	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death and Disease, 2013, 4, e738-e738.	6.3	30
39	p19INK4d Controls Hematopoietic Stem Cells in a Cell-Autonomous Manner during Genotoxic Stress and through the Microenvironment during Aging. Stem Cell Reports, 2014, 3, 1085-1102.	4.8	27
40	Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases. European Journal of Medical Genetics, 2018, 61, 715-722.	1.3	27
41	Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity. Blood, 2019, 133, 1778-1788.	1.4	27
42	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nature Communications, 2020, 11, 4886.	12.8	27
43	Concomitant germâ€line <i><scp>RUNX</scp>1</i> and acquired <i><scp>ASXL</scp>1</i> mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279.	2.2	25
44	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN1 \pm in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	1.4	25
45	Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin. Journal of Immunology, 2006, 176, 6425-6433.	0.8	21
46	Megakaryocyte polyploidization: role in platelet production. Platelets, 2020, 31, 707-716.	2.3	20
47	Immunophenotypic Study of Atypical Lymphocytes Generated in Peripheral Blood and Spleen of Nude Mice After MHV-72 Infection. Viral Immunology, 2000, 13, 313-327.	1.3	19
48	Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. Haematologica, 2016, 101, 1469-1478.	3.5	18
49	Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. Blood, 2016, 128, 3137-3145.	1.4	17
50	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica, 2018, 103, 575-586.	3.5	17
51	Mutations of the integrin αllb/β3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet αâ€granules. American Journal of Hematology, 2018, 93, 195-204.	4.1	17
52	An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. Blood, 2016, 128, 3146-3158.	1.4	16
53	Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia. Haematologica, 2019, 104, 1244-1255.	3.5	16
54	The cell division control protein 42–Src family kinase–neural Wiskott–Aldrich syndrome protein pathway regulates human proplatelet formation. Journal of Thrombosis and Haemostasis, 2016, 14, 2524-2535.	3.8	15

#	Article	IF	CITATIONS
55	Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica, 2016, 101, 1443-1445.	3.5	14
56	Germline <i>RUNX1</i> Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	2.7	13
57	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene, 2020, 39, 5323-5337.	5.9	12
58	The Bystander Effect Mediated by the New Murine Gammaherpesvirus 72 — Thymidine Kinase/5′-Fluoro-2′-Deoxyuridine (MHV72-TK/5-FUdR) Systemin Vitro. Antiviral Chemistry and Chemotherapy, 2000, 11, 273-282.	0.6	11
59	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preâ€leukaemic clone resulting in T2―ALL and AML â€MO. Journal of Cellular and Molecular Medicine, 2017, 21, 1237-1242.	3.6	10
60	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. ELife, 2021, 10, .	6.0	10
61	Murine gammaherpesvirus (MHV) M7 gene encoding glycoprotein 150 (gp150): difference in the sequence between 72 and 68 strains. Virus Genes, 2003, 26, 89-95.	1.6	8
62	A new heterozygous mutation in <i><scp>GP</scp>1<scp>BA</scp></i> gene responsible for macrothrombocytopenia. British Journal of Haematology, 2018, 183, 503-506.	2.5	8
63	The Pediatric Acute Leukemia Fusion Oncogene ETO2â€GLIS2 Increases Selfâ€Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cellsâ€Derived Model. HemaSphere, 2020, 4, e319.	2.7	8
64	Lyl-1 regulates primitive macrophages and microglia development. Communications Biology, 2021, 4, 1382.	4.4	8
65	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene, 2019, 38, 1651-1660.	5.9	7
66	First description of revertant mosaicism in familial platelet disorder with predisposition to acute myelogenous leukemia: correlation with the clinical phenotype. Haematologica, 2020, 105, e535.	3.5	6
67	An inherited gainâ€ofâ€function risk allele in <scp><i>EPOR</i></scp> predisposes to familial <scp> <i>JAK2 </i> ^{V617F} </scp> myeloproliferative neoplasms. British Journal of Haematology, 2022, 198, 131-136.	2.5	6
68	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Research, 2020, 44, 101755.	0.7	5
69	Role of Rho-GTPases in megakaryopoiesis. Small GTPases, 2021, 12, 399-415.	1.6	5
70	Dual role of EZH2 in megakaryocyte differentiation. Blood, 2021, 138, 1603-1614.	1.4	5
71	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e593.	2.7	5
72	p210BCR-ABL reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription. Leukemia, 2007, 21, 917-925.	7.2	4

#	Article	IF	CITATIONS
73	Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development. Stem Cell Research, 2020, 49, 102060.	0.7	4
74	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. Blood, 2021, 138, 480-485.	1.4	3
75	CK2: a key regulator of thrombopoiesis. Blood, 2017, 130, 2695-2697.	1.4	2
76	New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia. Blood, 2016, 128, 631-631.	1.4	2
77	New insights into regulation of $\hat{I}\pm IIb\hat{I}^2$ 3 integrin signaling by filamin A. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12672.	2.3	2
78	Interference of mouse polyomavirus with the c-myc gene and its product in mouse mammary adenocarcinomas. International Journal of Oncology, 2003, 23, 333.	3.3	1
79	From Hematopoietic Stem Cells to Megakaryocytes and Platelets. , 2008, , 162-177.		1
80	The megakaryocyte: a cell with 3 faces as a mythic god?. Blood, 2021, 138, 1199-1200.	1.4	1
81	Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells. Blood, 2016, 128, 1959-1959.	1.4	1
82	RUNX1-Induced Silencing of Non-Muscle Myosin lib (MYH10) Is Required for Megakaryocyte Polyploidization. Blood, 2011, 118, 1308-1308.	1.4	0
83	Abstract 2022: P53-dependent thrombocytopenia induced by the histone deacetylase inhibitor S78454. , 2012, , .		0
84	Modeling JAK2V617F Heterozygous and Homozygous Mutations by Using Induced Pluripotent Stem Cells Derived From Myeloproliferative Neoplasms Patients. Blood, 2012, 120, 1758-1758.	1.4	0
85	First case of a human <i>RASGRP2</i> mutation affecting Rap1 activation in platelets and causing severe bleeding Journal of Cell Biology, 2014, 206, 2061OIA111.	5.2	0
86	ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia. Blood, 2016, 128, 572-572.	1.4	0